Payment overview · 2025
General Payments
$5,093.54
202 reported records · 28 companies
Healthcare provider profile · identity verified
Ricardo Marques
Allopathic & Osteopathic Physicians|Internal Medicine · BOCA RATON, FL · NPI 1811957749
Verified facts
What the public records show
CMS Open Payments records show Ricardo Marques received $5,093.54 in general payments during 2025 across 202 reported records.
AstraZeneca Pharmaceuticals LP accounted for 27.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 46 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Linzess, Mounjaro, Ozempic, Synthroid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Mounjaro by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $1,379.66 | 27.1% | 44 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $524.89 | 10.3% | 17 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $467.63 | 9.2% | 14 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $442.49 | 8.7% | 25 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $353.65 | 6.9% | 16 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $287.71 | 5.7% | 9 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $258.35 | 5.1% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $209.62 | 4.1% | 12 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $201.69 | 4.0% | 15 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $167.11 | 3.3% | 9 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $166.45 | 3.3% | 9 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $92.88 | 1.8% | 4 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $55.04 | 1.1% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $52.40 | 1.0% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $46.90 | 0.9% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $46.63 | 0.9% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $45.29 | 0.9% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $42.04 | 0.8% | 2 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $41.25 | 0.8% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $35.68 | 0.7% | 2 | 2025 |
| Coherus Oncology, Inc. | Unresolved — no canonical attribution shown | $28.41 | 0.6% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $27.88 | 0.6% | 1 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $25.34 | 0.5% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $22.85 | 0.5% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $22.50 | 0.4% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $22.16 | 0.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.10 | 0.3% | 1 | 2025 |
| TMS NeuroHealth Centers Inc. | Unresolved — no canonical attribution shown | $9.94 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $5,093.54 | 202 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $693.43 | 15 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $499.89 | 16 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $446.15 | 13 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $412.51 | 13 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $353.65 | 16 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $287.71 | 9 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $258.35 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $246.79 | 10 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $224.63 | 13 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $223.41 | 10 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $220.11 | 12 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $201.69 | 15 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $200.26 | 10 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $177.76 | 14 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $166.45 | 9 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $133.38 | 7 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $133.38 | 7 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $128.13 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $115.50 | 6 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $92.88 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $84.79 | 6 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $70.28 | 5 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $55.04 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $52.40 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $51.61 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $48.84 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $48.84 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $46.90 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $45.29 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $42.04 | 2 | 2025 |
Source payment records
|
|||||
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $41.25 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $29.87 | 1 | 2025 |
Source payment records
|
|||||
| LOQTORZI Normalized: loqtorzi |
Biological | Coherus Oncology, Inc. | $28.41 | 1 | 2025 |
Source payment records
|
|||||
| Udenyca Normalized: udenyca |
Biological | Coherus Oncology, Inc. | $28.41 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $27.88 | 1 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $25.34 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $22.85 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $22.50 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $22.16 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.10 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.10 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $16.76 | 1 | 2025 |
Source payment records
|
|||||
| TMS NeuroHealth Centers Inc. Normalized: tms neurohealth centers inc |
Device | TMS NeuroHealth Centers Inc. | $9.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 67 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 42 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 50 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 63 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 100 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
50 | 21 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
42 | 15 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
67 | 23 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
42 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
63 | 13 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
100 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
67 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Alprazolam | Alprazolam | 666 | 115 |
| Methylprednisolone | Methylprednisolone | 512 | 298 |
| Atorvastatin Calcium | Atorvastatin Calcium | 487 | 172 |
| Pantoprazole Sodium | Pantoprazole Sodium | 385 | 151 |
| Amlodipine Besylate | Amlodipine Besylate | 319 | 116 |
| Ibuprofen | Ibuprofen | 314 | 151 |
| Levothyroxine Sodium | Levothyroxine Sodium | 273 | 87 |
| Tamsulosin Hcl | Tamsulosin Hcl | 251 | 91 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 232 | 162 |
| Metformin Hcl | Metformin Hcl | 230 | 82 |
| Lisinopril | Lisinopril | 216 | 81 |
| Omeprazole | Omeprazole | 214 | 72 |
| Azithromycin | Azithromycin | 212 | 147 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 193 | 67 |
| Losartan Potassium | Losartan Potassium | 191 | 65 |
| Gabapentin | Gabapentin | 183 | 90 |
| Zolpidem Tartrate | Zolpidem Tartrate | 176 | 47 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 167 | 66 |
| Temazepam | Temazepam | 162 | 31 |
| Simvastatin | Simvastatin | 154 | 47 |
| Furosemide | Furosemide | 141 | 56 |
| Metoprolol Succinate | Metoprolol Succinate | 137 | 49 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 128 | 66 |
| Prednisone | Prednisone | 121 | 53 |
| Glipizide | Glipizide | 118 | 43 |
| Escitalopram Oxalate | Escitalopram Oxalate | 114 | 45 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 111 | 87 |
| Ozempic | Semaglutide | 100 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 99 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 96 | 53 |
| Trazodone Hcl | Trazodone Hcl | 93 | 35 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 93 | 34 |
| Diclofenac Sodium | Diclofenac Sodium | 92 | 50 |
| Atenolol | Atenolol | 91 | 27 |
| Lorazepam | Lorazepam | 89 | 16 |
| Clobetasol Propionate | Clobetasol Propionate | 86 | 59 |
| Valacyclovir | Valacyclovir Hcl | 85 | 39 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 82 | 34 |
| Montelukast Sodium | Montelukast Sodium | 82 | 28 |
| Clonazepam | Clonazepam | 77 | 14 |
| Diazepam | Diazepam | 77 | 16 |
| Fenofibrate | Fenofibrate | 77 | 25 |
| Finasteride | Finasteride | 77 | 26 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 75 | 25 |
| Valsartan | Valsartan | 75 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 70 | 25 |
| Potassium Chloride | Potassium Chloride | 68 | 27 |
| Eliquis | Apixaban | 67 | 23 |
| Terbinafine Hcl | Terbinafine Hcl | 65 | 22 |
| Mounjaro | Tirzepatide | 63 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 59 | 20 |
| Meclizine Hcl | Meclizine Hcl | 59 | 38 |
| Carvedilol | Carvedilol | 54 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 54 | 24 |
| Levofloxacin | Levofloxacin | 53 | 37 |
| Sertraline Hcl | Sertraline Hcl | 53 | 19 |
| Testosterone Cypionate | Testosterone Cypionate | 53 | 18 |
| Allopurinol | Allopurinol | 50 | 21 |
| Linzess | Linaclotide | 50 | 21 |
| Meloxicam | Meloxicam | 48 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 45 | 17 |
| Alendronate Sodium | Alendronate Sodium | 44 | 15 |
| Repatha Sureclick | Evolocumab | 44 | 15 |
| Donepezil Hcl | Donepezil Hcl | 43 | 17 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 43 | 32 |
| Xarelto | Rivaroxaban | 43 | 13 |
| Anastrozole | Anastrozole | 42 | 14 |
| Famotidine | Famotidine | 42 | 13 |
| Jardiance | Empagliflozin | 42 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 40 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 39 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 38 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 37 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | 12 |
| Sildenafil Citrate | Sildenafil Citrate | 36 | 13 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 35 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 35 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 34 | 15 |
| Spironolactone | Spironolactone | 33 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 33 | 23 |
| Bumetanide | Bumetanide | 31 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | 18 |
| Nifedipine Er | Nifedipine | 31 | 12 |
| Ketoconazole | Ketoconazole | 30 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 30 | suppressed |
| Cephalexin | Cephalexin | 29 | 23 |
| Synthroid | Levothyroxine Sodium | 29 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Acyclovir | Acyclovir | 28 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 28 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 20 |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Ibu | Ibuprofen | 26 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Ezetimibe | Ezetimibe | 25 | 11 |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Fluconazole | Fluconazole | 25 | 15 |
| Glimepiride | Glimepiride | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | 12 |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Amoxicillin | Amoxicillin | 24 | 15 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 24 | 11 |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 23 | 21 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Premarin | Estrogens, Conjugated | 22 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 22 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 21 | 11 |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 20 | 12 |
| Lactulose | Lactulose | 20 | suppressed |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Vascepa | Icosapent Ethyl | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Metronidazole | Metronidazole | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Progesterone | Progesterone, Micronized | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Indomethacin Er | Indomethacin | 17 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Mupirocin | Mupirocin | 16 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Ciclopirox | Ciclopirox | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | 13 |
| Ssd | Silver Sulfadiazine | 14 | 12 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 13 | suppressed |
| Emtricitabine-Tenofovir Disop | Emtricitabine/Tenofovir (Tdf) | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 13 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $5,093.54 · 202 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, AREXVY, BREZTRI, CAMZYOS, CAPLYTA, COMIRNATY, CREON, Cologuard Collection Kit, DOVATO, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, FFRct, IBSRELA, JARDIANCE, Kerendia, LEQVIO, LINZESS, LOQTORZI, MOUNJARO, NURTEC ODT, OTEZLA, Ohtuvayre, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, SYNTHROID, Sunosi, Symbravo, TMS NeuroHealth Centers Inc., TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, Udenyca, VOQUEZNA, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZENPEP, ZEPBOUND, ZORYVE | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error